Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide

References

• Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clinic Proc 1975;50:29–40.
   PubMed Web of Science ®Google Scholar
• Oshima K, Kanda Y, Nannya Y, et al. Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma. Am J Hematol 2001;67:1–5.
   PubMed Web of Science ®Google Scholar
• Augustson BM, Begun G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005;23:9219–9226.
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009;49:1211–1225.
   PubMed Web of Science ®Google Scholar
• Mills KH, Cawley JC. Abnormal monoclonal antibody-defined helper/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage. Br J Haematol 1983;53:271–275.
   PubMed Web of Science ®Google Scholar
• Prabhala RH, Neri P, Bae JE, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006;107:301–304.
   PubMed Web of Science ®Google Scholar
• Brown RD, Pope B, Murray A, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001;98:2992–2998.
   PubMed Web of Science ®Google Scholar
• Ries LA, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2005 [Internet]. Available from: www.seer.cancer.gov
   Google Scholar
• Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431–436.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Hajek R, Tóthová E, et al. Thalidomide-dexamethasone compared to melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009;113: 3435–3442.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825–381.
   PubMed Web of Science ®Google Scholar
• Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomde versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma. Lancet 2007;370: 1209–1218.
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Piersantelli MN, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006;108:2159–2164.
   PubMed Web of Science ®Google Scholar
• Zervas K, Mihou D, Katodritou E, et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group. Ann Oncol 2007;18:1369–1375.
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813–1821.
   PubMed Web of Science ®Google Scholar
• Cesana C, Nosari AM, Klersy C, et al. Risk factors for the development of bacterial infections in patients with multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules. Haematologica 2003;88:1022–1028.
   PubMed Web of Science ®Google Scholar
• Facon T, Mary JY, Pégourie B, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006;107:1292–1298.
   PubMed Web of Science ®Google Scholar
• Hernandez JM, Garcia-Sanz R, Golvano E, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 2004;127: 159–164.
   PubMed Web of Science ®Google Scholar
• Shustik C, Belch A, Robinson S, et al. A randomized comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol 2007;136:203–211.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006;91:1068–1075.
   PubMed Web of Science ®Google Scholar
• Haslett PA, Corral LG, Albert M, et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998;187:1885–1892.
   PubMed Web of Science ®Google Scholar
• Haslett PA, Hanekom WA, Muller G, et al. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 2003;187:946–955.
   PubMed Web of Science ®Google Scholar
• Blanco B, Perez-Simon JA, Sanchez-Abarca LI, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006;107:3575–3583.
   PubMed Web of Science ®Google Scholar
• Heider U, Rademacher J, Kaiser M, et al. Decrease in CD4+ T cells in multiple myeloma patients receiving bortezomib. Blood 2009;114(Suppl. 1): Abstract 3865.
   Google Scholar
• Nucci M, Anaissie E. Infections in patients with multiple myeloma. Semin Hematol 2009;46:277–288.
   PubMed Web of Science ®Google Scholar
• Hargreaves RM, Lea JR, Griffiths H, et al. Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol 1995;48:260–266.
   PubMed Web of Science ®Google Scholar
• Perri RT, Hebbel RP, Oken MM. Influence of treatment and response status on infection risk in multiple myeloma. Am J Med 1981;71:935–940.
   PubMed Web of Science ®Google Scholar
• Savage DG, Lindenbaumn J, Garret TJ. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med 1982;96:47–50.
   PubMed Web of Science ®Google Scholar
• Nelson S. Novel nonantibiotic therapies for pneumonia: cytokines and host defense. Chest 2001;119:419S–425S.
   Google Scholar
• Juffermans NP, Verbon A, Schultz MJ, et al. Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens. Antimicrob Agents Chemother 2001;45:1547–1549.
   PubMed Web of Science ®Google Scholar
• Horvath CJ, Ferro TJ, Jesmok G, et al. Recombinant tumor necrosis factor increases pulmonary vascular permeability independent of neutrophils. Proc Natl Acad Sci USA 1988;85:9219–9223.
   PubMed Web of Science ®Google Scholar
• Zhang P, Summer WR, Bagby GJ, et al. Innate immunity and pulmonary host defense. Immunol Rev 2000;173:39–51.
   PubMed Web of Science ®Google Scholar
• Kroger K, Weiland D, Ose C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006;17:297–303.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007;110:2339–2346.
   PubMed Web of Science ®Google Scholar
• Weill-Engerer S, Meaume S, Lahlou A, et al. Risk factor for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter study. J Am Geriatr Soc 2004;52: 1299–1304.
   PubMed Web of Science ®Google Scholar